| EPB188 | Antiretroviral Therapy (ART) use among pregnant enrollees receiving medicaid managed care | E-poster | Adherence |
| EPB187 | Viral load suppression after intensive adherence counselling among HIV infected adults at Kiswa health centre, Kampala: a retrospective cohort study. Secondary data analysis | E-poster | Adherence |
| EPB186 | Early implementation and clinical outcomes of long-acting injectable cabotegravir and rilpivirine in a safety-net HIV clinic | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB185 | Preference for long acting injectable (LAI) antiretrovirals for HIV treatment or PrEP in Argentina | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB184 | Injection site reaction experience in clinical studies of people using lenacapavir for HIV treatment | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB183 | Week 96 weight and lipid changes from baseline among participants receiving cabotegravir and rilpivirine long-acting or comparator therapy in the ATLAS-2M and FLAIR studies | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB182 | Long-acting cabotegravir+rilpivirine injection site reactions: pooled Week 96 results | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB181 | 'Give it a Shot': best practices from HCPs for administering long-acting cabotegravir+rilpivirine | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB180 | Long-acting cabotegravir+rilpivirine in older adults: pooled Phase 3 Week 96 | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB179 | Initiating long-acting cabotegravir and rilpivirine in a real-world setting ' clinical characteristics and switch reasons from people living with HIV (PLHIV) and health care provider perspective in the German CARLOS cohort | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |